Daniela Manno, Catriona Patterson, Abdoulie Drammeh, Kevin Tetteh, Mattu Tehtor Kroma, Godfrey Tuda Otieno, Bolarinde Joseph Lawal, Seyi Soremekun, Philip Ayieko, Auguste Gaddah, Abu Bakarr Kamara, Frank Baiden, Muhammed Olanrewaju Afolabi, Daniel Tindanbil, Kwabena Owusu-Kyei, David Ishola, Gibrilla Fadlu Deen, Babajide Keshinro, Yusupha Njie, Mohamed Samai, Brett Lowe, Cynthia Robinson, Bailah Leigh, Chris Drakeley, Brian Greenwood, Deborah Watson-Jones
We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period immediately after dose 1 and after dose 2 vaccinations. Previous malaria exposure in participants in an Ebola vaccine trial in Sierra Leone (ClinicalTrials.gov: NCT02509494) was classified as low, intermediate, and high according to their antibody responses to a panel of Plasmodium falciparum antigens detected using a Luminex MAGPIX platform...
August 2, 2023: Vaccines